Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
Desensitization to sulfasalazine was successful in 40/47 (85%) patients with IBD who previously had hypersensitivity reactions. The desensitization with sulfasalazine was well-tolerated with no serious complications in short- or long-term follow-up. The course of IBD was subsequently favorable in 35/40 (87%) for extended periods including 17/17 (100%) with ulcerative colitis. Desensitization should be attempted in patients who have had typical hypersensitivity reactions to sulfasalazine.
D002986:Clinical Trials as Topic; D003092:Colitis / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D003888:Desensitization, Immunologic; D003875:Drug Eruptions / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D012460:Sulfasalazine